Epigral Ltd · NSE:EPIGRAL
Epigral — Q4 FY2024 Earnings Presentation
19 slides from Epigral's earnings presentation, Apr 22, 2024
Slide 1: Exchange filing cover letter for Q4 & FY2024 presentation
22.04.2024 To, National Stock Exchange of India Limited BSE Limited “Exchange Plaza”, Floor- 25, P J Tower, Bandra-Kurla Complex, Dalal Street, Bandra (East) Mumbai 400 051 Mumbai 400 001 SYMBOL:- EPIGRAL Scrip Code: 543332 Dear Sirs, Sub.: Investors Presentation for Audited Financial Results – Q4 &
Slide 2: Q4 & FY2024 Earnings Presentation
Epigral Limited (formerly known as Meghmani Finechem Limited) Q4 & FY2024 Earnings Presentation
Slide 3: Disclaimer
Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Epigral Limited (the “Company”) solely for the information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities and shall not form
Slide 4: Company Overview
Company Overview Founded: 2007 33% 28% 4 Year Revenue CAGR (FY24) 4 Year EBITDA CAGR (FY24) Employees: ~ 1000 0.8x 17% Debt to Equity (FY24) ROCE (FY24) Capacity: Chlor-Alkali# – 421 KTPA Derivatives# – 235 KTPA Revenue from operations (₹ Cr) 2,188 1,929 Certified: 1,551 Responsible Care Certificate
Slide 5: Our Journey
Our Journey FY 2007 FY 2010 FY 2015 FY 2017 FY 2020 Epigral Ltd (MFL) Commissioned 1st Increased capacity to Commissioned Commissioned incorporated Plant • Caustic Potash – • Chloromethanes – • Caustic Soda – 167 21 KTPA 50 KTPA • Caustic Soda – 119 KTPA KTPA • CPP – 60 MW Converted all Announced Ca
Slide 6: Q4FY24 - Key Highlights
Q4FY24 - Key Highlights Q4FY24 Operational Highlights: o Volume grew 9% YoY and 4% QoQ. YoY major growth comes from new projects commissioned in FY2023 o Capacity utilization stood at 83% in Q4FY24 vs 81% in Q3FY24 and 77% in Q4FY23 o YoY realizations dropped for all the products in range of 15% to
Slide 7: FY2024 - Key Highlights
FY2024 - Key Highlights FY2024 Operational Highlights: o Despite challenging year, Epigral sales volume grew 15%. Volume from Derivatives & Specialty business grew around 30% and Chlor-alkali business grew around 7% o Capacity utilization stood at 78% in line with FY2023 o Realization for all the pr
Slide 8: FY2024 - Key Strategic Updates
FY2024 - Key Strategic Updates o Epigral board proposed final dividend of ₹ 5 per equity share (50% of face value) for FY2024 o Capex / Expansions o Epigral spent ₹ 405 Cr on capex for FY2024 o On 3rd April 2024, Epigral expands its CPVC Resin capacity to 75,000 TPA, by commissioning additional 45,0
Slide 9: CMD Message
CMD Message “Epigral performed better on sequential basis in every quarter starting from Q2FY24. Our 55% growth in PAT on a sequential basis stands out despite challenging macroeconomics, subdued demand and drop in realizations. We delivered volume growth of 15% in FY2024 and 9% YoY in Q4FY24, as we
Slide 10: Q4FY24 Financial Highlights
Q4FY24 Financial Highlights Revenue – YoY Growth: -7% EBIDTA – YoY Growth: 0% PAT – YoY Growth: 0% 562 30% 28% 26% 15% 525 14% 155 155 123 10% 77 77 472 49 Q4FY23 Q3FY24 Q4FY24 Q4FY23 Q3FY24 Q4FY24 Q4FY23 Q3FY24 Q4FY24 ₹ Cr Margin -%
Slide 11: FY2024 Financial Highlights
FY2024 Financial Highlights Revenue EBIDTA PAT 2,188 31% 16% 689 25% 1,929 353 10% 481 196 FY2023 FY2024 FY2023 FY2024 FY2023 FY2024 ₹ Cr Margin %
Slide 12: Key ratios as on 31st March 2024
Key ratios as on 31st March 2024 ROCE (%)*# ROE (%)* Net Debt/EBITDA (x)* 39% 1.99 32% 1.25 17% 17% FY2023 FY2024 FY2023 FY2024 FY2023 FY2024 *TTM EBIT, PAT and EBITDA are considered for above ratios #Capital employed in ROCE includes Capital Work in Progress
Slide 13: Revenue Transition towards Derivatives & Specialty Chemicals
Revenue Transition towards Derivatives & Specialty Chemicals 62% 62% 70% 56% 54% 52% 48% 55% 46% 44% 38% 38% 45% 30% Q4FY23 Q1FY24 Q2FY24 Q3FY24 Q4FY24 FY2023 FY2024 - Chlor-Alkali - Derivatives & Specialty Chemical
Slide 14: Project Update as on 31st March 2024
Project Update as on 31st March 2024 Capex Spends - ₹ Cr Expected % of project Product Capacity Commissioning completed Date CPVC Resin Commissioned 45 KTPA Q4FY24 (Additional) 3rd April 2024 416 405 Chlorotoluenes - Q2FY25 90% Value Chain 300 CPVC 35 KTPA Q1FY25 80% Compound - FY2023 FY2024 FY2025E
Slide 15: Focused on ESG
Focused on ESG ENVIRONMENT o Focused on using best technology to manage critical resources, to moderate the consumption of energy and natural resources and drive operations efficiently o Focus is to manufacture more from less, basis for environment responsibility o Entered in JV to set up 18.34 MW W
Slide 16: Income Statement
Income Statement Particulars (₹ Cr) Q4FY24 Q4FY23 YoY % Change Q3FY24 QoQ % Change Total Revenue 526 567 -7% 474 11% Gross Profit 230 224 3% 194 19% Gross Margin (%) 44% 40% 41% EBITDA 155 155 0% 123 27% EBITDA Margin (%) 30% 28% 26% Depreciation 30 30 1% 31 -2% Finance Cost 14 19 -28% 20 -32% PBT 1
Slide 17: Historic Income Statement
Historic Income Statement Particulars (₹ Cr) FY20 FY21 FY22 FY23 FY24 Total Revenue 613 831 1,555 2,196 1,936 Gross Profit 300 407 716 951 763 Gross Margin (%) 49% 49% 46% 43% 40% EBITDA 194 261 509 689 481 EBITDA Margin (%) 32% 32% 33% 31% 25% Depreciation 44 74 86 109 124 Finance Cost 11 29 44 66
Slide 18: Historic Balance Sheet
Historic Balance Sheet Assets (₹ Cr) FY22 FY23 FY24 Liabilities (₹ Cr) FY22 FY23 FY24 Fixed Assets 1,657 1,962 2,249 Share Capital 42 42 42 Financial Assets 8 28 29 Reserves & Surplus 684 1,028 1,213 Other Non-current Assets 11 23 14 Long-Term Borrowings 557 435 492 Inventories 154 212 263 Redeemabl
Slide 19: About Epigral and contact information
Epigral Limited (Epigral), formerly known as Meghmani Finechem Ltd, For further information incorporated in 2007, is a leading integrated manufacturer of chemicals in India. Epigral’s Dahej facility is a backward and forward integrated and Please log on to website - www.epigral.com automated complex